Tag: Hatch-Waxman Act

Generic Drug Patents Explained: Exclusivity Periods in US, EU, and Beyond

Generic Drug Patents Explained: Exclusivity Periods in US, EU, and Beyond
Allison Wood Jul 6 2026

Explore how generic drug patents and exclusivity periods differ across the US, EU, and other regions. Understand the impact of Hatch-Waxman, data exclusivity, and patent extensions on medication costs.

Read More >>

First Generic Approval: Why It Matters and What It Means for Drug Prices

First Generic Approval: Why It Matters and What It Means for Drug Prices
Allison Wood Jun 19 2026

Discover how first generic approval works under the Hatch-Waxman Act. Learn about the 180-day exclusivity, Paragraph IV certifications, and why this process saves patients billions in drug costs.

Read More >>

Effective Patent Life: Why Market Exclusivity for Drugs Is Shorter Than You Think

Effective Patent Life: Why Market Exclusivity for Drugs Is Shorter Than You Think
Allison Wood Jan 26 2026

Effective patent life for drugs is often just 10-15 years, not the full 20, because most of the patent term is used up during clinical trials and FDA review. Secondary patents and regulatory exclusivities extend this further, delaying generic competition.

Read More >>